TEL AVIV, Israel--(BUSINESS WIRE)--Compugen Ltd. (NASDAQ: CGEN)
today announced that the Company will host a conference call at 10:00 AM
ET on Tuesday, November 3, 2015 to review third quarter 2015 results.
The quarterly results will be released on the Company’s website (www.cgen.com),
prior to the conference call.
To access the conference call, please dial 1-888-668-9141 from the US,
or +972-3-918-0609 internationally. The call will also be available via
live webcast through Compugen’s website, located at the following link.
A replay of the conference call will be available approximately two
hours after the completion of the live conference call. To access the
replay, please dial 1-888-782-4291 from the US or +972-3-925-5925
internationally. The replay will be available through November 5, 2015.
About Compugen
Compugen is a leading drug discovery company utilizing its broadly
applicable predictive discovery infrastructure to identify novel drug
targets and develop first-in-class biologics. The Company’s current
pipeline primary focus is on immune checkpoint target candidates
discovered by the Company, potentially providing the basis for a next
wave of therapeutics for cancer immunotherapy. Compugen’s business model
is based on selectively entering into collaborations for its novel
targets and drug product candidates at various stages of research and
development under revenue-sharing agreements. The Company is
headquartered in Tel Aviv, Israel, with R&D facilities in Tel Aviv and
South San Francisco. At the US facilities, monoclonal antibody
therapeutic candidates are discovered and developed against the
Company’s novel target candidates. For additional information, please
visit Compugen's corporate website at www.cgen.com.